



ATS Labs  
1285 Corporate Center Drive  
Suite 110  
Eagan, MN 55121

**For Immediate Release**

**Eagan, MN – September 1, 2011** – ATS Labs, a leader in antimicrobial testing services, announced an investment from private equity firm Ampersand Capital Partners. This investment provides ATS Labs with a strong partner as the company seeks to extend its leadership in microbiology and virology testing services, and to capitalize on new market opportunities.

Doug Anderson, PhD, President and CEO of ATS Labs commented on the Ampersand investment: “We are very excited about our partnership with the team at Ampersand. They will provide strong support as ATS Labs continue to build on the solid reputation and foundation business we have built over the last decade. Ampersand’s experience in laboratory testing services will enable ATS Labs to further explore growth opportunities while at the same time maintaining its best-in-class scientific analysis and customer service.”

Herb Hooper, Managing General Partner with Ampersand stated, “ATS Labs is a trusted microbiology testing lab for many Fortune 500 companies and has a strong reputation within the regulatory agencies. We instantly recognized the solid business that Doug and his team have built and are excited to help them take the company to the next level.”

In connection with Ampersand’s investment, ATS Labs has formed a new Board of Directors. In addition to Doug Anderson and Herb Hooper, the Board includes: David Anderson, Principal at Ampersand; Peter Parker, Senior Advisor at Ampersand; Larry McCarthy, PhD, Venture Partner at Ampersand; and Tom Burnell, PhD. Dr. McCarthy and Dr. Burnell both bring extensive experience from the laboratory testing industry. Dr. McCarthy previously built Focus Diagnostics from a small regional lab to an international laboratory serving the clinical diagnostics and pharmaceutical services industries. Dr. Burnell previously served as the President of Eurofins US, providing laboratory testing services to a broad range of industries.

**About ATS Labs**

For over 18 years, ATS Labs has been a committed partner to its clients, providing a comprehensive range of microbiology, virology, and product chemistry services. ATS Labs has an unwavering commitment to technical leadership, GLP compliance and exceptional customer service. The company’s scientific data is of the highest quality and its reports have earned a distinguished record of acceptance with regulatory agencies in the U.S., Canada, and abroad. For more information: [www.ats-labs.com](http://www.ats-labs.com).

**About Ampersand**

Ampersand is a middle market private equity firm with a focus in two core sectors: Healthcare and Industrial. Within this core, Ampersand targets growth equity opportunities where it can be the first institutional investor. Ampersand’s unique blend of private equity and operating skills positions the firm to build value and drive long-term performance by working in support of the portfolio company management teams. For more information: [www.ampersandcapital.com](http://www.ampersandcapital.com).

For more information:

Susan Forsberg  
Director of Marketing and Business Operations  
ATS Labs  
651-379-5510  
[sue.forsberg@ats-labs.com](mailto:sue.forsberg@ats-labs.com)

Caroline Marple  
Director of Operations  
Ampersand Capital Partners  
781-239-0700  
[clm@ampersandcapital.com](mailto:clm@ampersandcapital.com)